HBV/HCV Coinfection in the Era of HCV-DAAs
| Autor: | Rashed Abdelaal, Beshoy Yanny, Mohamed El Kabany |
|---|---|
| Rok vydání: | 2019 |
| Předmět: |
Liver Cirrhosis
Male Hepatitis B virus Carcinoma Hepatocellular Hepatitis C virus Comorbidity Hepacivirus medicine.disease_cause Risk Assessment 03 medical and health sciences Liver disease 0302 clinical medicine Prevalence medicine Humans Hepatology Coinfection Transmission (medicine) business.industry Liver Neoplasms virus diseases Hepatitis C Hepatitis B medicine.disease Survival Analysis Virology United States digestive system diseases 030220 oncology & carcinogenesis Hepatocellular carcinoma Disease Progression Female 030211 gastroenterology & hepatology business |
| Zdroj: | Clinics in Liver Disease. 23:463-472 |
| ISSN: | 1089-3261 |
| Popis: | Epidemiologic studies suggest that 10% to 15% of patients infected with hepatitis C virus (HCV) are coinfected with hepatitis B virus (HBV) in the United States as a result of the shared modality of transmission, but the true prevalence is not known. The progression of liver disease to cirrhosis and hepatocellular carcinoma is generally faster in patients who are coinfected, and HCV is usually more predominant. Immunosuppression of the host or eradication of hepatitis C can change this paradigm, causing hepatitis B reactivation. This review describes HCV-HBV viral interactions, risks for reactivation, screening, and society guidelines for surveillance and treatment. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|